{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:06Z","timestamp":1786120266928,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/ftd.0b013e31823cdeac","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T01:24:05Z","timestamp":1325294645000},"page":"72-76","source":"Crossref","is-referenced-by-count":31,"title":["Posaconazole: The Case for Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"34","author":[{"given":"Susan J","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gomez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2710.2009.01055.x","article-title":"Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.","volume":"34","author":"Moton","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/AAC.01616-09","article-title":"Skin concentrations and pharmacokinetics of posaconazole after oral administration.","volume":"54","author":"Krishna","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.","volume":"50","author":"Sansone-Parsons","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1128\/AAC.00889-09","article-title":"Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1111\/j.1439-0507.2011.02020.x","article-title":"Optimising absorption of posaconazole.","volume":"54","author":"Green","year":"2011","journal-title":"Mycoses"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.01027-09","article-title":"Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.","volume":"54","author":"Kohl","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/AAC.00472-06","article-title":"Effects of age, gender, and race\/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.","volume":"51","author":"Sansone-Parsons","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/03007990903485056","article-title":"Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.","volume":"26","author":"AbuTarif","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1128\/AAC.00931-09","article-title":"Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications.","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/AAC.01325-10","article-title":"Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.","volume":"55","author":"Shields","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/QCO.0b013e3283184611","article-title":"Therapeutic drug monitoring for triazoles.","volume":"21","author":"Hope","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079906X167507","article-title":"Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1185\/030079907X187937","article-title":"Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e31823cdeac","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:18Z","timestamp":1786047858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201202000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31823cdeac","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}